195 related articles for article (PubMed ID: 12077916)
1. [FDG PET scan of metastases in recurrent medullary carcinoma of the thyroid gland].
Szakáll S; Bajzik G; Repa I; Miklovicz T; Dabasi G; Sinkovics I; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1280-3. PubMed ID: 12077916
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.
Szakáll S; Esik O; Bajzik G; Repa I; Dabasi G; Sinkovics I; Agoston P; Trón L
J Nucl Med; 2002 Jan; 43(1):66-71. PubMed ID: 11801705
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
5. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
Giraudet AL; Vanel D; Leboulleux S; Aupérin A; Dromain C; Chami L; Ny Tovo N; Lumbroso J; Lassau N; Bonniaud G; Hartl D; Travagli JP; Baudin E; Schlumberger M
J Clin Endocrinol Metab; 2007 Nov; 92(11):4185-90. PubMed ID: 17726071
[TBL] [Abstract][Full Text] [Related]
6. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
7. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
8. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
[TBL] [Abstract][Full Text] [Related]
10. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
[TBL] [Abstract][Full Text] [Related]
13. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
[TBL] [Abstract][Full Text] [Related]
14. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.
Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R
Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093
[TBL] [Abstract][Full Text] [Related]
15. Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma.
Esik O; Szavcsur P; Szakáll S; Bajzik G; Repa I; Dabasi G; Füzy M; Szentirmay Z; Perner F; Kásler M; Lengyel Z; Trón L
Cancer; 2001 Jun; 91(11):2084-95. PubMed ID: 11391589
[TBL] [Abstract][Full Text] [Related]
16. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.
Diehl M; Risse JH; Brandt-Mainz K; Dietlein M; Bohuslavizki KH; Matheja P; Lange H; Bredow J; Körber C; Grünwald F
Eur J Nucl Med; 2001 Nov; 28(11):1671-6. PubMed ID: 11702109
[TBL] [Abstract][Full Text] [Related]
18. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
19. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
20. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.
Faggiano A; Grimaldi F; Pezzullo L; Chiofalo MG; Caracò C; Mozzillo N; Angeletti G; Santeusanio F; Lombardi G; Colao A; Avenia N; Ferolla P
Endocr Relat Cancer; 2009 Mar; 16(1):225-31. PubMed ID: 19004986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
